NCT01423253

Major Depressive Disorder With Mixed Features - Extension

A 12-Week, Open-Label Extension Study For the Treatment of Major Depressive Disorder With Mixed Features

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Sumitomo Pharma America, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features over time.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Lurasidone	Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed

Timeline

• Start date: 2011-09-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2011-08-25
• Last updated: 2016-04-08
• Results posted: 2015-10-14

Locations

17 sites across 1 country: United States